Autopsy report · NCT00646763

A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation

“Accrual goal met”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 35 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Cytokines

Interventions

G-CSF, GM-CSF administered at extremities; G-CSF and GMCSF administered at abdomen

Participants

35

Sites

1

Countries

United States

Trials that died the same way

• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (75% match in meaning)
• Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors, Quality of Life and Lifestyle Outcomes
  “No accrual” (70% match in meaning)
• Afatinib in Advanced Refractory Urothelial Cancer
  “Unable to meet accrual goal after several years” (68% match in meaning)
• Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
  “Poor accrual” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.